Zinc picolinate
Based on 1 Customer Validation
Zinc picolinate is an orally effective zinc supplement. Zinc picolinate reduces the expression of Hsp70, inhibits oxidative DNA damage, increases serum ALP activity, decreases MDA concentration, elevates SOD levels, and raises zinc concentrations in serum, whole body and plasma. Zinc picolinate does not alter copper and manganese contents in rainbow trout. Zinc picolinate exerts a protective effect against Acetic acid (HY-Y0319)-induced experimental colitis in Sprague Dawley rats. Zinc picolinate reduces uterine fibroid volume, alleviates colonic oxidative damage, relieves colonic inflammation, and enhances intestinal barrier integrity. Zinc picolinate can be used in research related to uterine fibroids, ulcerative colitis and chronic obstructive pulmonary disease.
For research use only. We do not sell to patients.
- Purity: ≥97.0%
- CAS No.: 17949-65-4
- Formula: C12H8N2O4Zn
- Molecular Weight:309.58
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
Cytoskeleton Compound Library
HY-L060
-
Cuproptosis Compound Library
HY-L133
-
Metabolic Enzyme Compound Library
HY-L146
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
All DNA/RNA Synthesis Isoforms
More
Biological Activity
|
HSP70 |
Zinc picolinate (dietary zinc content 30-60 mg Zn/kg; oral administration; twice daily; for 55 days) linearly reduces oxidative stress (measured by MDA concentration) in rainbow trout, increases their serum ALP activity and tissue zinc levels, and does not affect their growth, feed intake, feed efficiency, or copper/manganese concentrations[2].
Zinc picolinate (6 mg/kg; i.p.; once daily; for 10 consecutive days) exerts a protective effect against acetic acid-induced ulcerative colitis in male Sprague Dawley rats by alleviating oxidative stress, inhibiting local and systemic inflammation, enhancing intestinal barrier integrity, and improving histopathological outcomes, while significantly reducing colonic TNF-α levels and histopathological scores[3].
Zinc picolinate (6 mg/kg; i.p.; once daily; for 10 consecutive days) regulates the expression of colonic cytokines and tight junction proteins in healthy male Sprague Dawley rats, significantly increases colonic TNF-α levels, decreases colonic IL-6, occludin-1 and claudin-1 levels, and does not alter macroscopic or histopathological results[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Coturnix coturnix japonica (6-month-old)[1]
-
Dosage:30 mg/kg of diet; 60 mg/kg of diet
-
Administration:p.o.; ad libitum daily; 350 days
-
Result:Showed no significant difference in tumor incidence between treatment and control groups (10% for 30 mg/kg group, 14% for 60 mg/kg group, vs. 16% control).
Reduced average tumor diameters significantly: 2.6 mm for the 30 mg/kg group and 2.9 mm for the 60 mg/kg group, compared to 4.8 mm in controls (P = .01).
Reduced serum oxidative stress markers significantly in a linear dose-dependent manner (P = .01): serum MDA was 1.34 μmol/L (30 mg/kg) and 0.93 μmol/L (60 mg/kg) vs. 1.95 μmol/L control; serum 8-isoprostane was 93 pg/mL (30 mg/kg) and 85 pg/mL (60 mg/kg) vs. 108 pg/mL control; serum HAE was 1.21 μmol/L (30 mg/kg) and 0.96 μmol/L (60 mg/kg) vs. 1.55 μmol/L control; serum 8-OHdG was 23.6 ng/mL (30 mg/kg) and 20.1 ng/mL (60 mg/kg) vs. 28.5 ng/mL control.
Decreased Hsp70 expression in fibroid tissue significantly in a dose-dependent manner (P < .05), with densitometric readings showing ~73% of control levels for the 30 mg/kg group and ~39% of control levels for the 60 mg/kg group.
-
Animal Model:Oncorhynchus mykiss (0+ y-old, initial average weight 50 g)[2]
-
Dosage:30 mg Zn/kg of diet; 60 mg Zn/kg of diet
-
Administration:p.o.; twice daily; 55 days
-
Result:Decreased serum malondialdehyde (MDA) concentration to 1.12 nmol/mL, liver MDA to 3.30 nmol/mL, and muscle MDA to 2.15 nmol/mL at 30 mg Zn/kg of diet.
Decreased serum MDA concentration to 0.92 nmol/mL, liver MDA to 2.94 nmol/mL, and muscle MDA to 1.63 nmol/mL at 60 mg Zn/kg of diet.
Increased serum alkaline phosphatase (ALP) activity to 115 U/L, serum Zn concentration to 13.8 μg/mL, and whole body Zn concentration to 47.8 μg/g at 30 mg Zn/kg of diet.
Increased serum ALP activity to 138 U/L, serum Zn concentration to 15.6 μg/mL, and whole body Zn concentration to 52.0 μg/g at 60 mg Zn/kg of diet.
Did not significantly alter body weight gain, feed intake, feed efficiency, or serum/whole body Cu and Mn concentrations at either dose compared to unsupplemented controls.
Decreased serum, liver, and muscle MDA concentrations linearly (P=0.001) with increasing zinc picolinate dose.
Increased serum ALP activity (P=0.01), serum Zn (P=0.01), and whole body Zn (P=0.05) linearly with dose.
-
Animal Model:Sprague Dawley (male, 12-week-old, 250-300 g, acetic acid-induced ulcerative colitis)[3]
-
Dosage:6 mg/kg
-
Administration:i.p.; daily; 10 days
-
Result:Attenuated ulcer severity and significantly reduced macroscopic damage score (p < 0.01) and stool consistency score (p < 0.05).
Significantly increased serum zinc levels (p < 0.05).
Significantly reduced colon malondialdehyde (MDA) levels (p < 0.05) and increased colon glutathione (GSH) levels (p < 0.01).
Significantly reduced colon myeloperoxidase (MPO) activity (p < 0.01), serum tumor necrosis factor (TNF)-α levels (p < 0.05), serum interleukin (IL)-6 levels (p < 0.01), colon TNF-α levels (p < 0.001), and colon IL-6 levels (p < 0.001).
Significantly increased colon occludin mRNA expression (p < 0.001) and claudin-1 mRNA expression (p < 0.001), and significantly reduced zonula occludens-1 mRNA expression (p < 0.001).
Significantly reduced histopathological score (p < 0.001) and increased PAS-positive surface mucus and goblet cell count.
-
Animal Model:Sprague Dawley (male, 12-week-old, 250-300 g)[3]
-
Dosage:6 mg/kg
-
Administration:i.p.; daily; 10 days
-
Result:Showed no significant changes in macroscopic score, stool quality score, colonic edema score, colon MDA levels, colon GSH levels, colon MPO levels, serum TNF-α levels, serum IL-6 levels, or histopathological score compared to saline-treated healthy rats.
Significantly increased colon TNF-α levels (p < 0.05) and significantly reduced colon IL-6 levels (p < 0.01) compared to saline-treated healthy rats.
Significantly reduced colon occludin-1 mRNA expression (p < 0.001) and claudin-1 mRNA expression (p < 0.001) compared to saline-treated healthy rats; no significant change in zonula occludens mRNA expression.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 17949-65-4
-
Appearance Solid
-
Molecular Weight 309.58
-
Formula C12H8N2O4Zn
-
Color White to off-white
-
SMILES
O=C1[O-][Zn+2]2([N]3=C1C=CC=C3)[O-]C(C4=[N]2C=CC=C4)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sahin N, et al. Zinc picolinate in the prevention of leiomyoma in Japanese quail. J Med Food. 2009 Dec;12(6):1368-74. [Content Brief]
[3]. Han G, et al. Zinc Picolinate Mitigates Colonic Inflammation and Enhances Barrier Function in a Rat Model of Ulcerative Colitis. Biol Trace Elem Res. 2026 Apr;204(4):2285-2300. [Content Brief]
[4]. Kirkil G, et al. Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease. Respir Med. 2008 Jun;102(6):840-4. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Zinc picolinate Related Classifications
HY-W459577 Related Classifications
Powered by Bioz